FL-ELEVATE-PRIZE-FNDTN
10.3.2021 15:02:05 CET | Business Wire | Press release
The Elevate Prize Foundation is pleased to announce the launch of its second year of the Elevate Prize, which will commit $5 million in funding and services to 10 prize winners. The Foundation is searching for social impact leaders globally who are tackling the most pressing challenges of our time, with the most innovative and effective solutions.
Founders and CEOs of nonprofits and public charities worldwide are welcome to apply to win one of 10 annual Elevate Prizes. New this year is a simplified, two-phase application, making it significantly easier for nonprofit leaders to apply for the Prize. Phase 1, now open to all applicants, includes a shortened written application, while Phase 2 will include a more robust set of questions, released only to select applicants this summer.
The Elevate Prize Foundation, founded in 2019 by entrepreneur and philanthropist Joseph Deitch , is dedicated to giving unsung social entrepreneurs the necessary resources to scale their impact, and to ultimately help inspire and awaken the hero in all of us. The Foundation awarded its inaugural class of 10 winners in October 2020.
Each winner of this year’s Elevate Prize will receive:
- MONEY . A minimum of $300,000 (USD) shared between winners and their nonprofit organizations, so they can collectively drive change.
- AMPLIFICATION . Our strategic marketing and media expertise can take winners to the next level. Be a social impact influencer. Find fans. Build a platform. Think bigger. Do great things. Change the world.
- MENTORSHIP . Our network of partners, executives and decision-makers offer the kind of professional development and business guidance money can’t buy.
- CONNECTIONS . Each cohort is a radically diverse group of people leading innovative organizations. As a member of this cohort, winners will have the opportunity to learn from each other, create shared experiences, and build lasting relationships.
- SUPPORT . We take the time to thoroughly understand winners’ needs as an individual and organization, and then create a tailored program that will help each winner reach their goals and beyond.
“The Elevate Prize remains committed to finding a radically diverse group of innovative problem solvers, and investing unconventional and personalized resources that bring greater visibility to them as leaders and the vital work they do. We make good famous,” said Carolina García Jayaram, executive director, Elevate Prize Foundation.
The Foundation is proud to partner with MIT Solve on this year’s Elevate Prize. As an extension of its partnership, the Foundation will commit one of its 10 Prizes to MIT Solve’s first US Challenge on Antiracist Technology. The Elevate Prize for Antiracist Technology is open to nonprofit leaders who are helping to create an antiracist and equitable future in the U.S. This exemplar leader will take part in both the MIT Solver program and the Elevate Prize program and receive ongoing support from both organizations.
The application process for the Prize begins today at www.elevateprize.org/apply and applicants can submit up until the May 5 deadline. Following this deadline, select applicants will be invited to complete Phase 2 of the application. Winners will be announced in October 2021.
About the Elevate Prize Foundation
Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, the Elevate Prize Foundation aims to elevate humanity on a global scale by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize – a search for innovators and activists that culminates with the selection of 10 leaders to receive funding and guidance to amplify their work. These changemakers are working to solve the world’s problems within healthcare, the environment, poverty, inequality, the arts, and more. Elevate Prize winners embark on a two-year program fueled by access to top scholars and industry leaders who guide and support them in scaling their impact. Together, Prize winners, advisors, partners, and collaborators across industries combine their impressive reach to create a single, powerful philanthropic amplification platform to awaken the hero in all of us. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook, Instagram, LinkedIn, and Twitter.
About MIT Solve
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005111/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
